Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price
LTRN•Analyst coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell".
The average consensus recommendation for the biotechnology and medical research peer group is "buy".
Wall Street's median 12-month price target for Lantern Pharma Inc is $17.50, about 565.4% above its August 13 closing price of $2.63.
Q2 loss and warrant expenses
Lantern Pharma said its second-quarter loss from operations fell about 25% year over year, while its net loss widened on non-cash warrant expenses tied to a higher stock price.
The company reported a Q2 loss per share of $0.57.
Outlook and clinical programs
The company said it intends to pursue additional capital raises, collaborations and other opportunities to extend its operating runway.
Lantern plans to initiate a .
